Roche announces positive results from phase III study of Gazyva/Gazyvaro in people with lupus nephritis: Basel Friday, September 27, 2024, 12:00 Hrs [IST] Roche announced positive ...
First clinical data of VO659 demonstrated 28% mean reduction in CSF mutant HTT at day 85 in HD patients in 40 mg dose cohort with an effect after the first dose No sustained ...